# Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)

> **NCT01026090** · PHASE4 · TERMINATED · sponsor: **Sanofi** · enrollment: 292 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Dronedarone
- **DRUG:** Placebo (for dronedarone)

## Key facts

- **NCT ID:** NCT01026090
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 292 (ACTUAL)
- **Why stopped:** 'Sponsor decision following recruitment issues, not related to any safety concerns in the study
- **Last updated:** 2014-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01026090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01026090, "Dronedarone Pattern of Use in Patients Scheduled for Elective Cardioversion (ELECTRA)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01026090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*